Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial.
Horibe K, Morino K, Miyazawa I, Tanaka-Mizuno S, Kondo K, Sato D, Ohashi N, Ida S, Yanagimachi T, Yoshimura M, Itoh R, Murata K, Miura K, Arima H, Fujita Y, Ugi S, Maegawa H; SUMS-ADDIT-2 Research group.
Horibe K, et al. Among authors: yoshimura m.
Diabetes Res Clin Pract. 2022 Apr;186:109781. doi: 10.1016/j.diabres.2022.109781. Epub 2022 Feb 15.
Diabetes Res Clin Pract. 2022.
PMID: 35181350
Clinical Trial.